Brilinta approval in US - Future treatment paradigm in ACS to evolve with experience and upcoming clinical data from Effient studies

July 2011 | 4 pages | ID: BC14E62F217EN
MP Advisors

Abstracts

Yesterday, the long awaited approval for Brilinta in ACS in the US finally came in. The approval comes with a black box warning of increased bleeding and restriction of concomitant Aspirin dosage to < 100mg. We forecast 50% market share for Brilinta in ACS, which should translate into ww peak sales of $2.5b. Genericization of Plavix in 2012, twice daily dosing and restriction of concomitant aspirin dosage to <100mg will be potential deterrents to an initial robust uptake of Brilinta. As physician gain experience with the use of Brilinta and Effient, they will tailor the usage of anti-platelet agents that best fits depending on the patient demographics, history, age, and coexisting risk factors.

Contents

COMPANIES MENTIONED

ASTRAZENECA, BRISTOL-MYERS SQUIBB, ELI-LILY